Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
PaperCitations, authors & open-access status
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 371 citations, 2019 year and green oa status.
371
Citations
2019
Year
green
OA Status